CORRECTION

[View Article Online](#)
[View Journal](#) | [View Issue](#) Cite this: *Chem. Sci.*, 2020, 11, 897**Correction: O²-3-Aminopropyl diazeniumdiolates suppress the progression of highly metastatic triple-negative breast cancer by inhibition of microvesicle formation *via* nitric oxide-based epigenetic regulation**Fenghua Kang,^a Jiayi Zhu,^a Jianbing Wu,^a Tian Lv,^a Hua Xiang,^{id b} Jide Tian,^c Yihua Zhang^{id *a} and Zhangjian Huang^{id *a}

DOI: 10.1039/c9sc90256b

rsc.li/chemical-science

Correction for 'O²-3-Aminopropyl diazeniumdiolates suppress the progression of highly metastatic triple-negative breast cancer by inhibition of microvesicle formation *via* nitric oxide-based epigenetic regulation' by Fenghua Kang *et al.*, *Chem. Sci.*, 2018, 9, 6893–6898.

The authors regret that in the original article two incorrect images were used in Fig. 4b for representing migration tumor cells in the control and TGF- β + **3f** (20 nM) groups, and two incorrect images were used in Fig. 4c for representing invasive tumor cells in the TGF- β + **3f** (10 nM) and TGF- β + **3f** (20 nM) groups.

^aState Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Drug Discovery, China Pharmaceutical University, Nanjing 210009, China. E-mail: zyhtgd@163.com; zhangjianhuang@cpu.edu.cn

^bDepartment of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China

^cDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, California 90095, USA

Fig. 4 (a) 3f inhibited adhesion of MDA-MB-231 cells to HUVECs: fluorescence microscopy showed MDA-MB-231 cells (green) adhered to the HUVECs. $**P < 0.01$. (b) 3f inhibited migration of MDA-MB-231 cells. (c) 3f inhibited invasion of MDA-MB-231 cells. (d) 3f inhibited lateral migration of MDA-MB-231 cells. Data are shown as mean $\pm$ SD from each group. Scale bars, 100 μ m.

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.